Objective: To quantify the tracheostomy‐related morbidity and mortality, readmissions, and airway interventions in tracheostomy‐dependent children with bronchopulmonary dysplasia (BPD).Study Design: Retrospective chart review.Setting: Tertiary care children's hospital.Methods: Infants with BPD who received tracheostomy by an otolaryngologist between January 2016 and December 2022 at a single institution were included. Surviving patients were followed to at least 2 years of age. Data were extracted from electronic medical records for patient characteristics, clinical encounters, and surgical visits.Results: There were 76 patients included in this study. The overall mortality was 30.3% (23/76) with one tracheostomy‐related death. Tracheostomy occurred at a median 56 weeks postmenstrual age (PMA). Tracheitis was the most common short‐ and long‐term adverse event (within the first postoperative week, 21%; after postoperative day 7, 81%). Other complications observed include stomal granuloma (77%), airway stenosis (69%), and accidental decannulation (38%). The 30‐day and 2‐year readmission rates were 32% and 61%, of which 61% and 76% were for tracheostomy‐related causes, respectively. The most common reason for readmission over these time periods was tracheitis. Overall decannulation rate for surviving patients was 68%, and decannulation occurred at a median 3.1 years of age. Most surviving patients returned for operative airway intervention (85%); 43% required open airway reconstruction.Conclusion: Tracheostomy‐related morbidity was low in this cohort despite a majority of patients experiencing multiple tracheostomy‐related adverse events and readmissions. Patient comorbid conditions, BPD severity, and socioeconomic status were not significantly associated with outcomes. Larger studies are needed to assess the airway interventions and outcomes in this population.
Objective: In 2022, the U.S. Supreme Court decision on Dobbs v. Jackson Women’s Health Organization changed abortion access. We evaluated birth rates of Down syndrome (DS) before and after the Dobbs decision hypothesizing similarity to cyanotic congenital heart disease. Study design: Retrospective cohort study of live births utilizing 2016 – 2025 CDC birth certificate registry data stratified by DS and by state abortion access categories (restrictive and protective) based on the Guttmacher Institute. Incidence of DS and the difference in incidence between state cohorts were modeled and compared between pre- and post-Dobbs periods using segmented linear regression. Results: Incidence of DS live births remained stable in restrictive and protective states pre- and post-Dobbs. Segmented regression models revealed no significant changes in monthly incidence in the post-Dobbs era nationally compared to pre-Dobbs. Conclusions: Mean monthly incidence of DS in live-born infants using CDC birth certificate data did not increase after the Dobbs decision.
30 October 2026 in Journal of Pediatric and Adolescent Gynecology
Sickle cell disease (SCD) encompasses a spectrum of genotypes, most commonly Hemoglobin (Hgb)SS and HgbSC. Diastolic dysfunction (DD) is common in SCD and impacts morbidity and mortality. We sought to evaluate if the rates of DD differed by SCD genotype and by hydroxyurea (HU) use among youths. This was a retrospective study of patients with HgbSS and HgbSC who received an echocardiogram, stratifying genotype and HU use. DD was assessed using mitral valve (MV) E/A ratio < 0.8 or > 2, septal E’ < 7 cm/s, lateral E’ 10; and LA: Aortic root (LA: Ao) ratio > 1.3:1. DD was defined as a diastolic aggregate score ≥ 2 of 5. Multivariable regression models adjusted for age were used to estimate the associations of DD with HU use by genotype. 39% of youth with SCD who had an echocardiogram had DD. DD rates were lower in those on HU ( n = 102, 36%) vs. those not on HU ( n = 94, 41%). Adjusting for age, youths with HgbSS on HU had lower odds of DD compared to those not on HU, OR 0.22 [95% CI (0.07, 0.59), p = 0.004]. Conversely, youth with HgbSC on HU had slightly increased odds of DD compared to those not on HU, OR 1.36 [95% CI (0.35, 4.98) p = 0.6]. In contrast to previous studies suggesting HU has no impact in reducing DD over time, our study showed DD was less common among patients with HgbSS on HU. Larger, prospective, multi-center studies are needed to assess longitudinal improvement of DD from baseline for SCD patients on HU.
13 November 2025 in Journal of the Society for Cardiovascular Angiography & Interventions
Percutaneous radiofrequency (RF) wire pulmonary valve perforation (PVP) in pulmonary atresia/intact ventricular septum (PA/IVS) is a high-risk procedure. This study compared procedural efficacy and complications between RF and chronic total occlusion (CTO) wire PVP. This multicenter study included patients with PA/IVS who had PVP attempted at 13 centers. Outcomes of interest were efficacy and complications. Univariable logistic regression models were used to estimate odds ratios and risk differences. PVP was attempted in 206 patients; median age 3.0 days (1.0-6.0) and weight 3.1 kg (2.7-3.5). The RF PVP was attempted first in 165 (80.0%) patients, CTO in 27 (13.1%), and stiff end of the coronary wire in 14 (6.8%). The procedural success rate of 94% was similar between wire types. CTO group utilized smaller initial valvuloplasty balloons (2.25 mm [2-3] vs 4 mm [3-6]) and >2 balloons in 71% of cases (vs 18% in RF). Overall and major procedural complications occurred in 26.5% versus 12.5% (odds ratios [OR], 2.5 [0.8-11.1]; P = .15) and 14.8% vs 4.2% (OR, 4.0 [0.8-73.2]; P = .18), respectively, of RF versus CTO groups. Major postprocedural complications occurred in 12% versus 4.2% of the RF versus the CTO groups. Cases with multiple (vs single) PVP attempts had higher overall (40.4% vs 17.0%; OR, 3.3 [1.7-6.6]; P < .01) and major (24.6% vs 8.5%; OR, 3.5 [1.5-8.3], P < .01) procedural complication rates. PVP remains an effective treatment strategy in PA/IVS. Complication rate differences between CTO and RF wires may be clinically relevant. Further studies with larger cohorts are warranted to confirm findings and guide optimal intervention strategies.
1 April 2026 in Circulation: Genomic and Precision Medicine
BACKGROUND: Genetic variation affects clinical outcomes, prognosis, and family planning decisions in individuals with congenital heart disease (CHD). While genetic testing recommendations for infants and children with CHD have expanded, similar broad guidelines are lacking for patients with adult CHD (ACHD). Here, we investigated the current state of genetic testing in patients with ACHD and their perceptions toward testing, which has not been previously reported. METHODS: A single-center prospective cohort survey of patients with ACHD aged ≥18 years was evaluated in a large ACHD clinic over a 12-month period. RESULTS: Among 336 survey respondents (median age, 29 years; 52% male), CHD lesions were wide ranging, albeit largely represented by conotruncal (35%) or left ventricular outflow tract (35%) lesions. Most patients did not have children (64%) or a family history of CHD (79%). Thirteen percent had evidence of prior genetic testing despite 41% to 98% meeting criteria by current pediatric recommendations. Most desired genetic testing (68%) though interest varied by sex, education level, and family status. Individual and family health factors were reported as the most influential considerations for genetic testing. CONCLUSIONS: Few patients with ACHD have had genetic testing despite most being eligible based on current pediatric guidelines, likely related to birth era. Patients were interested in genetic testing though demographic factors and family status affected interest. The lack of broad recommendations for genetic testing in the ACHD population likely represents a significant barrier to increased utilization of genetic tests.